316 related articles for article (PubMed ID: 31570469)
1. Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Chiyonaga S; Motohara T; Komohara Y; Hara A; Akahoshi S
Anticancer Res; 2019 Oct; 39(10):5695-5701. PubMed ID: 31570469
[TBL] [Abstract][Full Text] [Related]
2. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
3. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.
Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Tanaka H; Hirai K; Sakamoto I; Ogawa T; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Feb; 15(1):177-184. PubMed ID: 34811701
[TBL] [Abstract][Full Text] [Related]
4. [A Case of Unresectable Hepatocellular Carcinoma Treated using Lenvatinib and Conversion Surgery].
Utsunomiya T; Sakamoto K; Iwata M; Ito C; Sakamoto A; Matsui T; Shine M; Nishi Y; Uraoka M; Nagaoka T; Tamura K; Funamizu N; Ogawa K; Kitazawa R; Takada Y
Gan To Kagaku Ryoho; 2022 Dec; 49(12):1365-1367. PubMed ID: 36539251
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
Namba M; Kawaoka T; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Chayama K
Clin J Gastroenterol; 2019 Aug; 12(4):341-346. PubMed ID: 30706429
[TBL] [Abstract][Full Text] [Related]
6. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
[TBL] [Abstract][Full Text] [Related]
7. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
9. Huge Hepatocellular Carcinoma Treated with Radical Hepatectomy after Drug-eluting Bead Transarterial Chemoembolization.
Fujita M; Okai K; Hayashi M; Abe K; Takahashi A; Kimura T; Kenjo A; Marubashi S; Hashimoto Y; Ohira H
Intern Med; 2019 Apr; 58(8):1103-1110. PubMed ID: 30626806
[TBL] [Abstract][Full Text] [Related]
10. Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma.
Ishizaki M; Kaibori M; Matsushima H; Kosaka H; Matsui K; Sekimoto M
Clin J Gastroenterol; 2021 Dec; 14(6):1700-1705. PubMed ID: 34480729
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.
Ichida A; Akamatsu N; Nagata R; Mihara Y; Kawaguchi Y; Bae SK; Ishizawa T; Kaneko J; Arita J; Hasegawa K
Anticancer Res; 2022 Feb; 42(2):1161-1167. PubMed ID: 35093921
[TBL] [Abstract][Full Text] [Related]
12. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
[TBL] [Abstract][Full Text] [Related]
13. A case of Vp4 hepatocellular carcinoma with tumor thrombosis extending into the confluence of the splenic/portal vein achieved a good prognosis with emergent hepatectomy and postoperative adjuvant therapy with lenvatinib.
Kato H; Asano Y; Ito M; Arakawa S; Shimura M; Koike D; Ochi T; Yasuoka H; Kawai T; Higashiguchi T; Tani H; Kunimura Y; Kondo Y; Nagata H; Sato H; Horiguchi A
World J Surg Oncol; 2022 Sep; 20(1):278. PubMed ID: 36057621
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic factors and outcome in patients with intrahepatic recurrence after hepatectomy for hepatocellular carcinoma].
Yang LT; Cheng XD; Du YA; Wang XB; Zhang YL; Guo JM
Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):612-6. PubMed ID: 20021950
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
[TBL] [Abstract][Full Text] [Related]
16. A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report.
Gyoda Y; Ichida H; Kawano F; Takeda Y; Yoshioka R; Imamura H; Mise Y; Fukumura Y; Saiura A
Clin J Gastroenterol; 2024 Apr; 17(2):311-318. PubMed ID: 38277091
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma.
Shindoh J; Kawamura Y; Kobayashi Y; Kobayashi M; Akuta N; Okubo S; Suzuki Y; Hashimoto M
Ann Surg Oncol; 2021 Nov; 28(12):7663-7672. PubMed ID: 33904001
[TBL] [Abstract][Full Text] [Related]
18. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
[TBL] [Abstract][Full Text] [Related]
19. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.
Komatsu S; Yano Y; Kido M; Kuramitsu K; Gon H; Fukushima K; Urade T; So S; Yanagimoto H; Toyama H; Kodama Y; Fukumoto T
Anticancer Res; 2021 Sep; 41(9):4555-4562. PubMed ID: 34475083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]